The holy grail: pan-cancer-targeting T cells

Crowther and Dolton et al. identified an unconventional human T cell clone capable of killing many different types of cancer in vitro in an HLA-independent fashion while sparing healthy cells. Using genome-wide CRISPR-Cas9 screening, the researchers showed that the T cell clone recognized the ubiquitously expressed, mostly monomorphic, MHC-I-related protein MR1 on the surface of cancer cells when MR1 was loaded with a yet unidentified cancer-specific or cancer-associated ligand. Adoptive transfer of this T cell clone into immunodeficient NSG mice with leukemia reduced tumor burden and increased survival.

Skeleton Key” T-Cell Receptor Works across Multiple Cancer Types

Advances in Targeting CAR-T Therapy for Immune-Mediated Diseases

Targeting KRAS in pancreatic adenocarcinoma: Progress in

IJMS, Free Full-Text

Biology, Free Full-Text

Pan-cancer T cell atlas links a cellular stress response state to

Frontiers γδ T cells as a potential therapeutic agent for

Michael G King Jr (@MichaelGKingJr) / X

Frontiers Effects of the interactions between platelets with

Ferroptosis: a double-edged sword mediating immune tolerance of

Frontiers Progress Toward Identifying Exact Proxies for

Novel strategies for cancer immunotherapy: counter-immunoediting

CIMT Annual Meeting 2022

WHO EMRO, Journée internationale du cancer de l'enfant 2022–2023, Campaigns

Alimentation et cancer, pendant et après - Cancers - Cerin

Filière IA & Cancers

Subscribe to Biochimica et Biophysica Acta: Reviews on Cancer

Risk of Cancer After Diagnosis of Cardiovascular Disease